President Trump on Thursday claimed his recent “most favored nation” executive order could cause U.S. drug prices to “drop like a rock” in just a matter of weeks, saying ...

Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on chromosomal instability, today announced preliminary safety and efficacy data from its ongoing, first-in-human Phase ...

Changes in blood are detectable at age 50 and universal by 60, paving the way for spotting early signs of unhealthy aging.

Regeneron Pharmaceuticals has announced that it will be acquiring human genetics and biotechnology company 23andMe for $256m.

Researchers have developed a new suite of genetic tools for cell-type specific targeting to battle brain disease.

Following President Donald Trump's most favored nation executive order, HHS and CMS have released the target price for ...

Regeneron Pharmaceuticals enters into asset purchase agreement to acquire 23andMe for $256 million: Tarrytown, New York Wednesday, May 21, 2025, 13:00 Hrs [IST] Regeneron Pharmace ...

Regeneron Pharmaceuticals REGN has emerged as the successful bidder in the bankruptcy auction for most of the assets of 23andMe Holding Co., a prominent player in human genetics and biotechnology.

Regeneron Pharmaceuticals announced Monday it plans to purchase human genetics and biotechnology firm 23andMe from bankruptcy ...

Regeneron intends for 23andMe to continue its consumer genome services without interruption. The transaction, pending ...

Regeneron Commits to Comply with Company's Privacy Policy and All Applicable Law; No Changes to 23andMe's Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO ...

The experiments will be conducted during the upcoming AXIOM-4 mission to the ISS, now scheduled to launch on June 8 from NASA ...